Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Chemomab Therapeutics ( (CMMB) ).
On May 15, 2025, Chemomab Therapeutics announced its first-quarter financial results and a significant corporate update, highlighting positive 48-week data from the SPRING trial of nebokitug in patients with primary sclerosing cholangitis (PSC). The company achieved alignment with the FDA on a regulatory pathway for nebokitug, potentially positioning it as the first FDA-approved treatment for PSC. The trial data indicated continued improvements in key biomarkers of liver injury, inflammation, and fibrosis, supporting the advancement of nebokitug to a Phase 3 trial. Chemomab is also exploring multiple partnering options to further the nebokitug program, with a cash runway extended to the second quarter of 2026.
The most recent analyst rating on (CMMB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Chemomab Therapeutics stock, see the CMMB Stock Forecast page.
Spark’s Take on CMMB Stock
According to Spark, TipRanks’ AI Analyst, CMMB is a Underperform.
Chemomab Therapeutics’ overall stock score is low due to significant financial challenges, including zero revenue and sustained losses. The technical analysis indicates mixed signals but does not currently show strong upward trends. The valuation metrics reflect high risk without profitability or income generation. The company’s future performance heavily relies on its ability to develop and commercialize products successfully.
To see Spark’s full report on CMMB stock, click here.
More about Chemomab Therapeutics
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet needs.
Average Trading Volume: 373,268
Technical Sentiment Signal: Sell
Current Market Cap: $23.76M
For a thorough assessment of CMMB stock, go to TipRanks’ Stock Analysis page.